Clinical trials · Boston, MA
Lymphoma clinical trials in Boston
We’re tracking 113 recruiting lymphoma studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT07128641RecruitingPhase 2
Odronextamab for early follicular lymphoma without prior treatment
This trial tests a new immunotherapy drug, odronextamab, for people with slow-growing follicular lymphoma that hasn't been treated yet and isn't causing big problems. It aims to see if the drug can control the cancer with fewer side effects.
Boston, MassachusettsAges 18 years+ - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Boston, MassachusettsAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Boston, MassachusettsAges 18 years+ - NCT07226843RecruitingPhase 1
Study of a new drug for adults with certain blood cancers
This trial tests a new drug, LY4584180, for adults with several types of non-Hodgkin lymphoma who have already had at least two prior treatments. The goal is to see if the drug can help shrink tumors and stop the cancer from growing.
Boston, MassachusettsAges 18 years+ - NCT05533775RecruitingPhase 1/Phase 2
Study of an antibody medicine with or without chemotherapy for relapsed lymphoma
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
Boston, MassachusettsAges 6 months–30 years - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Boston, MassachusettsAges 6 months–25 years - NCT06745076RecruitingPhase 2
Personalized chemotherapy reduction for advanced Hodgkin lymphoma
This trial tests a personalized approach to using a blood test (ctDNA) to decide how much chemotherapy you need. If you have advanced Hodgkin lymphoma, this study might let you have less chemo if the blood test shows a strong response early on, potentially reducing side effects.
Boston, MassachusettsAges 18 years+ - NCT04855695RecruitingPhase 1/Phase 2
Study for relapsed mantle cell lymphoma using targeted oral drugs
This Phase 1/2 study tests a combination of oral and antibody treatments for mantle cell lymphoma that has come back (relapsed) or did not respond (refractory). It aims to control the cancer and uses blood/tumor test results to guide some treatment timing for eligible participants.
Boston, MassachusettsAges 18 years+ - NCT07104032RecruitingPhase 3
Tirabrutinib vs standard therapy for relapsed PCNSL
This study tests a new oral targeted drug called tirabrutinib against a standard treatment combination (rituximab plus temozolomide) for people whose primary central nervous system lymphoma has come back or not responded to prior therapy.
Boston, MassachusettsAges 18 years+ - NCT06500273RecruitingPhase 2
Cema-cel for high-risk lymphoma after first treatment
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
Boston, MassachusettsAges 18 years+ - NCT07231952RecruitingPhase 2
Study of pirtobrutinib, venetoclax, and rituximab for Waldenström's macroglobulinemia
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
Boston, MassachusettsAges 18 years+ - NCT06534060RecruitingPhase 2
Testing MB-105 for CD5 positive T-cell lymphoma
This trial tests a new treatment called MB-105 for people with a type of T-cell lymphoma that has come back or not responded to other treatments. MB-105 is designed to target and attack cancer cells that have a specific marker called CD5 on their surface.
Boston, MassachusettsAges 18 years+ - NCT06811272RecruitingPhase 2
Epcoritamab for older or frailer adults with large B-cell lymphoma
This trial tests an outpatient treatment called epcoritamab for people with large B-cell lymphoma who are older or frail, or who have already tried one treatment. The goal is to see if this drug can help control the cancer with fewer side effects than standard therapies.
Boston, MassachusettsAges 18 years+ - NCT06563596RecruitingPhase 2
Study of epcoritamab, zanubrutinib, and rituximab for relapsed lymphoma
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06742996RecruitingPhase 3
Sonrotoclax plus zanubrutinib for relapsed mantle cell lymphoma
This trial tests a new combination of two targeted therapies for people with mantle cell lymphoma that has come back or hasn't responded to prior treatment. It aims to see if adding sonrotoclax to zanubrutinib works better than zanubrutinib alone.
Boston, MassachusettsAges 18 years+ - NCT07014293Recruiting
Building resilience in early lymphoma survivors
This study looks at ways to help people feel stronger and cope better after finishing lymphoma treatment. If your lymphoma is under control, you may join to learn skills that improve your emotional well-being.
Boston, MassachusettsAges 18 years+ - NCT05607420RecruitingPhase 1/Phase 2
Testing a new cell therapy for relapsed lymphoma with CD20/CD22
This Phase 1/2 trial studies UCART20x22, a lab-made cell therapy, for people with certain types of relapsed or treatment-resistant B-cell non-Hodgkin lymphoma (NHL). It may help by targeting lymphoma cells that carry CD20 and/or CD22 markers and then testing safety and early effectiveness.
Boston, MassachusettsAges 18–80 - NCT06697184RecruitingPhase 1/Phase 2
Testing a slower start of sonrotoclax for blood cancers
This trial tests a new way to slowly increase the dose of the drug sonrotoclax when starting treatment for blood cancers like chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). The goal is to see if this slower start is safer and better tolerated.
Boston, MassachusettsAges 18 years+ - NCT05783609RecruitingPhase 2
Epcoritamab and rituximab for untreated follicular lymphoma
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
Boston, MassachusettsAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Boston, MassachusettsAges 18 years+ - NCT05800366RecruitingPhase 2
Testing glofitamab plus polatuzumab for high-risk diffuse lymphoma
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
Boston, MassachusettsAges 18 years+ - NCT06849713RecruitingPhase 2
New combination treatments for CLL or SLL
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
Boston, MassachusettsAges 18 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Boston, MassachusettsAges 1–21 - NCT06098430Recruiting
Quality of life in NLPHL patients
This study looks at how people with a rare type of Hodgkin lymphoma (NLPHL) feel about their health and quality of life. By filling out surveys, you can help doctors understand what really matters to patients like you.
Boston, MassachusettsAges 8 years+
Hear when a new Lymphoma trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Lymphoma trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting lymphoma studies listed above.
- Dana-Farber Cancer Institute · 15 studies
- Beth Israel Deaconess Medical Center · 7 studies
- Massachusetts General Hospital · 7 studies
- Beth Israel Deaconess Medical Center (Data Collection Only)
- Dana Farber Cancer Institute (Data Collection and Specimen Analysis)
- Dana Farber Cancer Institute Longwood Medical Center
- Harvard Medical School - Massachusetts General Hospital
- Mass General Brigham
What taking part in a lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting lymphoma studies in Massachusetts.
Common questions
- Are there lymphoma clinical trials near Boston?
- Yes. We're currently tracking 113 recruiting lymphoma studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lymphoma study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lymphoma studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.